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Background: The objective of this study was to develop a rating tool for policy makers to prioritize breast cancer
interventions in low- and middle- income countries (LMICs), based on a simple multi-criteria decision analysis
(MCDA) approach. The definition and identification of criteria play a key role in MCDA, and our rating tool could be
used as part of a broader priority setting exercise in a local setting. This tool may contribute to a more transparent
priority-setting process and fairer decision-making in future breast cancer policy development.
Methods: First, an expert panel (n = 5) discussed key considerations for tool development. A literature review
followed to inventory all relevant criteria and construct an initial set of criteria. A Delphi study was then performed
and questionnaires used to discuss a final list of criteria with clear definitions and potential scoring scales. For this
Delphi study, multiple breast cancer policy and priority-setting experts from different LMICs were selected and invited
by the World Health Organization. Fifteen international experts participated in all three Delphi rounds to assess and
evaluate each criterion.
Results: This study resulted in a preliminary rating tool for assessing breast cancer interventions in LMICs. The tool
consists of 10 carefully crafted criteria (effectiveness, quality of the evidence, magnitude of individual health impact,
acceptability, cost-effectiveness, technical complexity, affordability, safety, geographical coverage, and accessibility), with
clear definitions and potential scoring scales.
Conclusions: This study describes the development of a rating tool to assess breast cancer interventions in LMICs. Our
tool can offer supporting knowledge for the use or development of rating tools as part of a broader (MCDA based)
priority setting exercise in local settings. Further steps for improving the tool are proposed and should lead to its useful
adoption in LMICs.
Keywords: Multi-criteria decision analysis, Priority setting, Breast cancerBackground
As the second most common cancer in the world and
the most common cancer in women, breast cancer is an
important health problem globally [1]. Although it was
originally considered to be a disease of the developed
world, low- and middle-income countries (LMICs) are
experiencing large increases in incidence [2]. Mortality-
to-incidence rates remain relatively high in these areas
[3], possibly due to relatively poor breast cancer control* Correspondence: kristievenhorst@gmail.com
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unless otherwise stated.strategies (e.g. awareness raising, early detection, treat-
ment) and differences in cultural beliefs [2,4]. Because
strong early detection programs are beneficial, the
World Health Organization (WHO) seeks to improve
appropriate breast cancer control programs in LMICs.
Cost-effectiveness analyses (CEAs), based on the maxi-
mization of health benefits, have often been used for the
selection of breast cancer control strategies. To provide
an evidence base for the cost-effectiveness of breast can-
cer interventions in LMICs, a consortium of the WHO,
Erasmus University Rotterdam, the Radboud University
Nijmegen Medical Center, and the Susan G. Komen for
the Cure Foundation initiated an international study inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to spend scarce health care resources more efficiently.
However, decision-makers often deviate from CEA re-
sults because other principles such as equal treatment
and priority to the worst-off [6-8] and other factors like
feasibility or acceptability influence decisions, as well
[9-11]. Ignorance about these criteria may induce imple-
mentation problems or inequality among certain patient
groups [12-14].
Multi Criteria Decision Analysis (MCDA) is a well-
accepted framework that can simultaneously assess
multiple criteria for priority setting of interventions
[15]. Different approaches of MCDA are proposed but
contain at least the following elements: 1) selection of
relevant interventions, 2) selection of criteria for priority
setting, 3) collecting evidence and rating the performance
of interventions on selected criteria, 4) deliberation on the
evidence and performance of interventions with the aim to
select the best interventions for implementation [16-19].
Several studies have shown the potential of MCDA in
prioritizing health interventions, however, it has not yet
been applied for the selection of breast cancer control
interventions [20-23]. Recently, MCDA has been criticized
for being technocratic and conceptually challenging for
local decision makers [24]. Therefore, the development of
a tool to support local policy makers in selecting criteria
and in rating the performance of interventions on these
criteria is warranted.
The objective of this study is to develop a rating tool
to assess breast cancer interventions along the con-
tinuum of care, within the context of the overarching
breast cancer CEA project [5]. The rating tool will be
composed of criteria, criteria definitions, criteria weights
and rating scales to measure the overall impact of breast
cancer interventions and support the priority setting
process. Such a rating tool can be used in a broader,
MCDA based, priority setting process to develop cancer
control strategies in a local setting.
Methods
To develop the rating tool we established an expert
panel (n = 5) of breast cancer and priority-setting experts
from WHO and the Radboud University Nijmegen
Medical Centre. The expert panel consisted of two health
economists, a scientific researcher, a public health special-
ist and a student on health technology assessment. Three
of the experts are co-authors of this article (KV, SZ and
JL). A detailed overview of the considerations made by the
expert panel in the development of the rating tool is pro-
vided as additional information (Additional file 1). Below
we describe the most important steps that were taken to
develop the tool.
A literature search using PubMed and Google Scholar
was performed for the identification of a first set ofpredefined criteria. Different combinations of the terms
‘criteria’, ‘values’, ‘factors’, ‘priority setting’, ‘decision making’,
and ‘policy making’ were used as the query. The expert
panel discussed the list in order to avoid overlap among
the criteria. For the remaining criteria, clear definitions
were defined with the help of glossaries and documents
published by the WHO [25-27].
To develop the scoring scales, another literature study
was performed for each criterion of this predefined list.
When no or little information was available, scoring
scales were mainly based on discussions with the expert
panel.The Delphi study
The list of predefined criteria and scoring scales was fur-
ther refined by the opinion of experts from all over the
world. A Delphi study was chosen because of the anonym-
ity of participants, the opportunity to include participants
globally, and the time and money available to conduct the
study [28]. Delphi studies have proven to be appropriate
for finding a core list of evaluation criteria [29].Participants
Experts were selected following WHO selection criteria
that include a balanced geographical and gender repre-
sentation, expertise in the technical area (particularly in
LMICs), and absence of any relevant interest in the per-
sonal declaration of interest form. Twenty-nine experts
with expertise in priority setting or breast cancer pol-
icies in LMICs were involved, ensuring methodological
as well as substantive quality. Experts were identified by
approaching authors of relevant articles and by snowball
sampling. Among the experts there were epidemiologists,
cancer survivors, pathologists, guideline-developers, public
health specialists, radiotherapists, surgeons, researchers,
managers, strategists and ethicists.First round
In this round, the list with criteria based on the performed
literature study was presented to the participants. The
participants were asked to score the criteria on five-point
Likert scales, according to whether they agreed that in-
terventions scoring high on the criterion should be more
prioritized (1 = strongly disagree, 2 = disagree, 3 = neutral,
4 = agree, 5 = strongly agree). The experts could give
comments on the list and mention whether important
criteria were missing. In addition, the definitions and
scoring scales of the criteria were presented and partici-
pants were asked to provide comments. Likert scales were
chosen for this first round because this method is reviewed
as acceptable for a Delphi study and is simple and easy to
perform [30].
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This second round showed the scores and comments
given in the first round, together with the adaptations to
which they had led. Subsequently, participants were asked
whether they agreed on the adaptations and if they could
clarify their answers.
Third round
Based on the proportion of participants agreeing on the ad-
aptations made after the first round and on the comments
provided, some final changes were made to the criteria list.
These final criteria and their definitions and scoring scales
were shown to the participants, who were asked whether
they agreed that this final list contained the most relevant
criteria for the prioritization of breast cancer interventions.
Furthermore, participants were asked to divide 100 points
over the criteria according to their relative importance for
the evaluation of breast cancer interventions.
The analysis
The analysis of the answers was both quantitative and
qualitative. After the first Delphi round, mean and median
scores on the Likert scales for “the importance” of criteria
were calculated. The second round resulted in a percentage
of participants who agreed with the suggested adaptations.
After the third round, the mean and median weights given
according to the importance of criteria were calculated. All
participant comments were quantitatively analyzed.
Results
The literature search on criteria resulted in a total of 33
criteria (Figure 1). After the expert panel discussed theseFigure 1 Overview of the development of the criteria list.criteria, nine criteria remained for the Delphi study.
Two criteria, effectiveness and feasibility, were divided
into three and four subcomponents. For each of these
nine criteria and the subcomponents, a definition and a
potential scoring scale were defined.
Participants
Out of 72 experts who were asked, 29 were willing to
participate. Of these, 17 were experts on priority setting,
and 12 were experts on breast cancer policies. The first
questionnaire was completed by 23 participants, the
second questionnaire by 19 participants, and the third
questionnaire by 15 participants. Reasons for not com-
pleting a questionnaire were private circumstances and
disagreement with the aim of this research (n = 1). Most
participants, however, gave no reason.
First round
Based on the results of the first round, two criteria
(‘Severity of breast cancer’ and ‘Age’) and one of the
components (‘The time until the effect emerges’) were
suggested for removal; two of the components were
suggested to be combined with two criteria; and all the
other components were suggested for separation into
different criteria. Also, a new criterion was suggested
(‘Political will’), two definitions were refined, and four
scoring scales were adapted. These adaptations led to a
list of 10 criteria. For all criteria, except for the criter-
ion ‘Effectiveness’, there was divergence in Likert scale
scores. The average and median Likert scale values and
most important comments on the criteria are shown in
Table 1.
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Based on the results of the second round, the new sug-
gested criterion (‘Political will’) was removed again be-
cause participants argued that political will would also
depend on the results of interventions on the other cri-
teria; political will changes too often; and MCDA aims
at a more fair priority-setting process while politicalTable 1 Initial criteria including Likert scores and important c
Average
likert scores
Median
likert scores
Range of
likert scores
M
Effectiveness 4.75 5 4-5 Ef
th
cr
Size of effectiveness 4.70 5 3-5 N
Certainty of the
evidence
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Feasibility 4.23 4 2-5 Th
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Technical complexity 3.5 3.5 1-5 N
Capital intensity 3.75 4 1-5 Th
in
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Safety 4 4 2-5 Th
(p
ac
sh
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Age 3.29 3.5 1-5 A
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Magnitude of individual
health impact
3.83 4 1-5 N
Catastrophic health
expenditures
4.17 5 1-5 A
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it.
be
hewill might even be clearly unfair. Two criteria (‘Equal
access’ and ‘Acceptability’) were separated into two dif-
ferent criteria (‘Geographical coverage’ and ‘Accessibility’;
‘Acceptability’ and ‘Safety’); two criteria were combined
(‘Catastrophic health expenditures’ and ‘Acceptability’);
and some small refinements to most of the definitions and
scoring scales were made. An overview of the changesomments given in the Delphi study
ost important comments
fectiveness is covered by its components. Effectiveness should
erefore be removed and its components should be independent
iteria, otherwise they will overlap.
o important comments.
ot related to effectiveness only. The strength of the evidence varies
criterion for any given intervention. Much simpler and effective to
clude considerations of certainty of evidence in assigning scores for
l given criterion.
me preference for immediate effects goes against principles of
tergenerational equity, and is especially inappropriate for preventive
rvices. Therefore this criterion should be removed.
CDA might replace C/E. We can have costs but “effectiveness” is
fined by the sum of the criteria so adding this criterion introduces
uble-counting.
ficiency cannot be replaced by costs since higher costs do not per
mean lower efficiency as the effectiveness may be higher.
is should be four different criteria, otherwise they will overlap each
her.
e comments accessibility.
o important comments.
is criterion should not be limited to capital costs but also explicitly
clude operating costs required from the health system.
o important comments.
e importance of safety may vary with respect to whose safety
rovider vs. patient) and what is at stake, while the level of
ceptability may remain the same. Therefore acceptability and safety
ould be kept separated.
ccessibility due to geographical coverage of an intervention (‘Reach’)
not the same as accessibility due to socio-economic status. Therefore
is criterion should be about equal access for patients with different
cio-economic status, while geographical coverage should be covered
another criterion (‘Reach’)
f course I think that palliative care is very important. On the other hand,
you do nothing for all the people with earlier stage cancer, the cancer
ill progress and they will all need palliative care. So you could treat
ople with stage 1 or 2 cancer and most of them will not experience
te stage cancer, therefore will not need palliative care. I guess I don’t
d this a useful way to think about breast cancer.
ges of patients with breast cancer don’t seem appropriate even if one
anted to create prioritized age groups, which I wouldn’t.
o important comments.
ffordability is about whether the health system can afford an intervention
d catastrophic health expenditures is about whether patients can afford
Extreme health expenditures might however be covered by accessibility,
cause patients with lower socio-economic status cannot afford high
alth expenditures.
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round resulted in a final list of 10 criteria (Table 2).
Third round
All participants agreed that the list after the second round
covered the most relevant criteria for the prioritization of
breast cancer interventions. Three participants mentioned,
however, that some criteria might be still overlapping. As
one participant noted: “Doing the relative weighting exer-
cise above, I realized that some criteria are overlapping
and it was difficult to assess independent relative weights
to them; for example, ‘effectiveness’ and ‘quality of the evi-
dence’ are inseparable whereas we would not perhaps say
something is effective if the quality of the evidence is
weak”. There were also doubts about ‘cost-effectiveness’
being covered by the ‘affordability’ and ‘effectiveness’ and
about ‘safety’ being covered by ‘effectiveness’ and ‘geo-
graphical coverage’ being covered by ‘effectiveness’. The
criterion ‘geographical coverage’ was rated relatively low in
its importance for the evaluation of breast cancer inter-
ventions, followed by ‘safety’ and ‘affordability’, respect-
ively. The importance of the criterion ‘Effectiveness’ was
rated highest (Table 2).
Discussion
This study describes the development of a rating tool to
measure the impact of breast cancer interventions based
on multiple criteria in LMICs. Ten criteria, including defi-
nitions and potential scoring scales, have been indicated.
The results of this study show that effectiveness, quality
of the evidence, magnitude of individual health impact,
acceptability, cost-effectiveness, technical complexity, af-
fordability, safety, geographical coverage, and accessibility
seem to be important principles in the selection of breast
cancer control strategies. Although selecting and defining
interventions and criteria for breast cancer control is con-
text specific, we think that this rating tool can be a starting
point for local policy makers as part of a broader, MCDA
based, priority setting process.
Use of the tool in a LMIC
The tool could be used as part of the integrated MCDA
and accountability for reasonableness (A4R) approach
for priority setting, recently proposed by Baltussen et al.
[16] (Figure 2). This new approach combines strong
components of both frameworks and requires a set-up
of a multi-stakeholder consultation panel (step one). In
this way a democratic learning process is started in
which stakeholders are involved in all steps of the priority
setting. Compared to the stand-alone MCDA framework,
this combined approach may increase the acceptance of
decisions among stakeholders and the likelihood of imple-
mentation of prioritized programs. The rating tool can be
part of step two and three (Figure 1) of the approachthat aim to identify criteria for priority setting and
assess (i.e. rate) the performance of interventions on
the selected criteria.
An important next step in the local use of the rating
tool is to investigate how the tool and its components
are understood in LMICs in a pilot study. Users of the
tool could for example select relevant stakeholders (e.g.
patients, lay-people policy makers, caregivers, public
health specialists) and establish a consultation panel
(step 1). These stakeholders could discuss the interven-
tions, criteria, the attitude of decision-makers against
the criteria and scoring scales using democratic elements
(e.g. Nominal Group Technique) (step 2). After the col-
lection of all relevant (local) evidence, the users could
use our tool as an input for a performance matrix (step 3),
and then interpret and deliberate on the results of this
matrix (step 4 and 5). Users should be well informed and
plan enough time for this process, and should try to en-
sure that the tool is perceived as a simple and legitimate
way to frame policy discussions in a more rapid and
balanced manner. The potential of this tool could also
be investigated for other cancers.
Limitations of the study
Our study has a number of limitations. First, prior to the
Delphi study, the expert panel made a selection of 9
criteria out of 33 criteria. This selection was based on
overlap between criteria and whether criteria would be
appropriate for the selection of breast cancer interven-
tions. However, there is no certainty that personal pref-
erences did not lead to bias in this selection.
Second, we used Delphi studies to define a list with
core criteria including definitions and scoring scales.
The Delphi method ensures participant anonymity and
provides enough time to properly consider one’s own
answers and those of others. However, the Delphi ques-
tionnaire may not allow for adequate elaboration on
difficult concepts such as equity and social welfare.
Also, Delphi questionnaires can be relatively time con-
suming, which may have partly caused 14 participants
to withdraw from this study. We do not expect that
these withdrawals biased the results because they varied
in gender and type of expert and the number of com-
ments remained high in each questionnaire.
Third, the wide variety of comments and views of the
participants made us aware of the difficulties in developing
a clear, consensus-based, non-overlapping criteria list and
scoring scales. There are many possible compositions and
definitions of criteria [31-33]. Besides there are many ways
to divide a scoring scale into different categories and this
also depends on the variability of the interventions that
are considered (i.e. discriminative power of the scoring
scale). Further research should focus on more informed
contextualized categories for scoring scales.
Table 2 Final criteria list for the prioritization of breast cancer interventions including weights
Definition Potential scoring scales Average weight*
(min-max)
Median
weight
Effectiveness [31-35] Effectiveness is the extent to which an intervention impacts the
most relevant health-related outcomes (e.g. time to recurrence
or healthy life years gained). In comparison of effectiveness of
interventions, it is important to note that the most relevant
health-related outcome should be consistent for all interventions
under consideration [25].
Size of the effect (e.g. in a population of 1 million people): 17.33 (5–50) 15
0 less effective (e.g. < 50 healthy life years gained a year)
1 effective (e.g. ≥ 50 < 100 healthy life years gained a year)
2 very effective (e.g. ≥ 100 healthy life years gained a year) [36]
Quality of the evidence
[31,32,35,37,38]
The risk of bias and the extent of the confidence that the
evidence is adequate to support a particular decision or
recommendation [39].
0 very little or limited confidence in the evidence: the estimated
values may be substantially different from the outcomes in reality
11.93 (0–20) 12
1 moderately confident about the evidence: The estimated values
are likely to be close to the outcomes in reality, but there is a
possibility that it is different
2 very confident that the estimated values lie close to the
outcomes in reality [39]
Magnitude of individual
health impact [32,38]
Interventions offering small benefits for many may be viewed
differently from those offering large benefits for a few. When
one of the two is preferred above the other, interventions
providing the preferred effect (concentrated or dispersed) might
be more prioritized [32].
Scoring scale a could be used in the case that local stakeholders
decide that large individual health benefits are preferred above
helping more people.
8.60 (0–25) 10
Scoring scale b could be used in the case that local stakeholders
decide that helping more people is preferred above large
individual health benefits.
a
0 small individual health impact
1 moderate individual health impact
2 large individual health impact
b
0 benefits for just a few people.
1 benefits for a moderate number of people
2 benefits for many people
Acceptability
[26,34,35,38]
The extent to which the intervention is judged as suitable,
satisfying or attractive by different stakeholder groups
(e.g. patients, providers or politicians). The acceptability
depends on people their norms, beliefs and values [26,40].
0 the intervention is not accepted by some people and it is not
likely that this can be changed
8.67 (5–15) 10
1 the intervention is not accepted by some people but it is likely
that this can be changed with some extra effort (e.g. special
education)
2 the intervention is accepted by almost all people
Cost-effectiveness
[31,32,35,37,40]
The capacity to produce the maximum output for a given
monetary input [25].
0 not cost-effective (e.g. costs per gained healthy life year are
above 3*Gross Domestic Product (GDP) per capita)
12.4 (0–25) 15
1 cost-effective (e.g. costs per gained healthy life year are below
3*GDP per capita)
2 highly cost-effective (e.g. costs per gained healthy life year are
below 1*GDP per capita) [41]
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Table 2 Final criteria list for the prioritization of breast cancer interventions including weights (Continued)
Technical complexity
[26,34]
Other types of inputs required in addition to monetary
nputs to implement and to keep providing the intervention.
(These include human resource requirements, both
quantitative and qualitative, and organizational requirements.
The potential to integrate the intervention into an already
existing health system should also be taken into account [26].
Ability to train and deliver all clinical and organizational
requirements to run the intervention.
8.67 (5–15) 10
0 poor ability
1 moderately good ability
2 good ability
Affordability
[26,31,34,35,38]
The monetary input (e.g. capital investments and operational
costs) required from the health system to implement and to
keep providing the intervention [26].
0 poor affordability (e.g. costs > 1 US$ per capita) 8.47 (0–20) 10
1 moderate affordability (e.g. costs > 0.50≤ 1 US$ per capita)
2 good affordability (e.g. costs≤ 0.50 US$ per capita) [26]
Safety [31,34] Safety is the practical certainty that adverse effects to patients
or providers will not result from exposure to an intervention
under defined circumstances [27].
0 there is a risk of severe adverse effects (life threatening) to
patients or a risk of adverse effects (of any kind) to providers
7.87 (0–15) 10
1 there is a risk of mild adverse effects to patients
2 there is no risk or a risk of very mild adverse effects (adverse
effects which will completely recover within a month) to patients
Geographical coverage
[26,32,34,35]
The ability of the intervention to be reached by the target
population, independent of their living place [26].
0 the intervention does not cover (most) people who live far
away from cities.
5.47 (0 – 13) 5
1 the intervention does not cover some people who live far away
from cities.
2 the intervention covers (almost) all people
Accessibility [32,37] Patients with a different socioeconomic status or a different
income should be able to make equal use of the intervention [32].
0 the intervention is not accessible to many patients 10.6 (0 – 20) 13
1 the intervention is not accessible to some patients
2 the intervention is accessible to (almost) all patients
*weights were calculated by asking participants to divide 100 points over the criteria according to their relative importance for the evaluation of breast cancer interventions.
NOTE: References were used to identify the criteria in first instance. The Delphi study may have resulted in adaptations in definitions or scoring scales than originally found in the literature.
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Figure 2 Elements of a priority setting process based on MCDA [16].
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be explained by a lack of a broader theory on the rela-
tionship between criteria. Some disagreement between
participants remained until the end of the process, and
some overlap was still suspected in the final criteria list.
These potential overlaps will need attention in the fur-
ther development of this tool because criteria should
preferentially be independent from each other [15,42].
Especially effectiveness has a risk of overlap with other
criteria, like cost-effectiveness, safety and geographical
coverage. Further overlap between criteria should be
identified and distinctions should be made and clearly
described in the definitions.
Limitations of the tool
The tool also has some practical limitations that one
should be aware of. First, the tool does not provide guid-
ance to convert the performance matrix into a final
prioritization of interventions. This tool stops at rating
interventions after which a choice should be made based
on a democratic learning process (Figure 1). This tool
does not facilitate a democratic learning process, which
makes it less likely that good rated interventions are im-
plemented. The accountability for reasonableness frame-
work (A4R) is successful in introducing such a learning
process [43]. We recommend making the tool part of
the integrated MCDA A4R approach for priority setting
in health as proposed by Baltussen et al. [16], however
local capacity should be present or established to facili-
tate such a complete process.
Second, the proposed rating tool is based on decision-
maker values and preferences while the views of otherstakeholder groups are also considered important in pri-
ority setting exercises. Different stakeholder groups are
likely to have different preferences for criteria [22,44].
This limitation of the tool could be solved while apply-
ing the tool in a local setting. At that stage, other stake-
holder groups (like patients, the public, and health care
workers) can be asked to comment on the relevance of
the criteria included in the tool and the relative import-
ance and the tool can be adapted accordingly.
Third, there are limitations to the collection of infor-
mation, and it may sometimes be difficult to assess inter-
ventions on certain criteria. This is however a problem
across the field of health priority setting and we recom-
mend to be transparent on the available evidence and its
quality. A sensitivity analysis may help to give insight in
the uncertainty of the scoring performances of interven-
tion options. In this way, quality of evidence is not used
as a single criterion but as an uncertainty factor per cri-
terion per intervention [45].
Conclusion
This study describes the development of a rating tool to
assess the impact of breast cancer interventions on mul-
tiple criteria. This tool may be a starting point for local de-
cision makers that would like to conduct multi criteria
decision analysis to set priorities for breast cancer control.
Additional file
Additional file 1: Key considerations for the development of the
rating tool. In this additional file we elucidate on the key considerations
made for development of the rating tool.
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